Vitura Health CEO Geoff Cockerill Departs Jan 2026 as Board Seeks New Leader
Vitura Health (ASX: VIT) has announced the departure of Chief Executive Officer Geoff Cockerill, effective 28 January 2026, with interim leadership arrangements now in place as the Board advances its search for a permanent replacement. Ryan Tattle, Chief Revenue Officer, has assumed expanded responsibility for day-to-day management, supported by Shane Tanner’s transition from Non-Executive Director to Interim Executive Director.
The Board determined that new leadership was required to accelerate execution of the company’s strategic priorities as it continues focusing on improved financial and operational performance. The Vitura Health CEO transition reflects a decisive governance action during a transformation phase for the digital health business.
Interim leadership team brings operational continuity
Ryan Tattle brings extensive commercial experience and deep understanding of Vitura’s operations, having played a key role in the early stages of the company’s strategic reset and performance improvement initiatives. All Executive Leadership Team members now report directly to Tattle during the interim period.
Shane Tanner’s appointment as Interim Executive Director signals a short-term focused arrangement designed to support operational execution. His remuneration terms reflect this transitional nature.
| Role | Name | Key Detail |
|---|---|---|
| Interim Day-to-Day Leadership | Ryan Tattle | Chief Revenue Officer, led strategic reset initiatives |
| Interim Executive Director | Shane Tanner | Former Non-Executive Director, appointment until 30 April 2026 |
| Interim Executive Fee | Shane Tanner | $100,000 p.a. pro-rata (additional to Board fees) |
The interim arrangements provide continuity whilst allowing the Board to conduct a thorough search for permanent leadership. Tanner’s appointment may extend to 30 June 2026 if required, with either party able to terminate the engagement by providing 30 days’ written notice.
When big ASX news breaks, our subscribers know first
What a CEO transition means for ASX-listed companies
Leadership changes at ASX-listed companies follow established corporate governance practices designed to maintain operational stability whilst addressing strategic needs. The process typically involves interim arrangements, a structured search for permanent leadership, and clear communication with stakeholders.
Investors monitoring CEO transitions should focus on several key indicators:
-
Interim leadership qualifications – Whether acting executives possess operational knowledge and commercial experience relevant to the company’s current priorities
-
Timeline for permanent appointment – How quickly the Board expects to conclude its search and what criteria guide the selection process
-
Strategic continuity messaging – Whether the company’s stated priorities remain unchanged or require recalibration under new leadership
-
Operational performance during transition – How key business metrics and project milestones progress during the interim period
For companies undergoing transformation, execution-focused leadership becomes particularly significant. The ability to maintain momentum on performance improvement initiatives whilst managing day-to-day operations requires both operational expertise and strategic alignment with Board objectives.
Incoming CFO Andrew Cook to start ahead of schedule
Vitura has confirmed that Chief Financial Officer Andrew Cook will commence on 9 February 2026, ahead of expectations. This early start strengthens financial leadership continuity during the Vitura Health CEO transition period.
Cook brings over 20 years of international experience in senior finance roles across diverse industries. His track record spans large complex organisations including Energy Queensland, Origin Energy, and SABMiller. Most recently, he served as Chief Financial Officer and Company Secretary of AnteoTech Limited.
His experience across multiple sectors, from energy to consumer goods to biotechnology, suggests capability to navigate Vitura’s multi-business model. The company operates a diversified digital health portfolio spanning medicinal cannabis distribution (Canview), telehealth platforms (Doctors on Demand), specialist clinics, and a joint venture focused on psychedelic medicines.
The early CFO commencement provides operational momentum at a critical juncture. Financial discipline represents one of the company’s stated strategic priorities alongside operational excellence and strengthening its position as a healthcare services provider.
Board reaffirms strategic priorities
Chair Robert Iervasi emphasised continuity in the company’s direction despite the leadership change.
Chair Commentary
“The Company’s strategic priorities remained unchanged as it continues to focus on operational excellence, financial discipline, and strengthening its position as a trusted provider in the healthcare services sector.” — Robert Iervasi, Chair
This statement signals that Vitura’s transformation agenda continues under the interim leadership structure. The Board’s focus on execution capability in its CEO search aligns with these stated priorities.
The next major ASX story will hit our subscribers first
Next steps for Vitura Health investors
The Board has described its CEO search process as “advanced” and prioritised. Shareholders now have clear visibility on the transition timeline and interim arrangements.
Key dates and milestones to monitor:
-
9 February 2026 – CFO Andrew Cook commences
-
30 April 2026 – Initial conclusion date for Shane Tanner’s Interim Executive Director appointment
-
30 June 2026 – Potential extension date for interim arrangements if required
-
CEO appointment – Board aims to conclude search for experienced, execution-focused permanent leader
The structured approach to the Vitura Health CEO transition reduces execution risk during the transformation phase. Tattle’s existing role as Chief Revenue Officer and involvement in strategic reset initiatives provides operational continuity, whilst Tanner’s temporary executive appointment adds governance support without creating long-term structural changes.
Investors should track operational performance metrics and strategic initiative progress during this period. The company’s financial discipline focus, operational excellence targets, and healthcare services positioning remain the key criteria against which interim leadership effectiveness can be assessed.
The early arrival of the incoming CFO provides an additional layer of stability, particularly for financial reporting and capital management during a period of leadership transition. Cook’s experience in large complex organisations may prove valuable as Vitura seeks to optimise its multi-business digital health platform.
Want more Healthcare and Biotech breaking news?
Vitura Health’s leadership transition represents the type of governance action that can significantly impact share price trajectory and strategic execution. For investors tracking ASX Healthcare and Biotech sectors, staying informed of CEO changes, operational updates, and financial developments isn’t optional—it’s essential.
The Big News Blast from StockWire X delivers FREE breaking news alerts and comprehensive analysis covering Healthcare, Biotech, Technology, Finance, and Industrial sectors—every Non-Resource ASX opportunity that matters. With over 20,000+ active subscribers already receiving same-day alerts on executive changes, clinical trial results, regulatory approvals, and strategic pivots, readers gain the analytical edge needed to identify opportunities before the broader market reacts. Click the ‘Free Alerts’ button to join a community of informed investors who refuse to miss the next significant development in Australia’s most dynamic growth sectors.